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ABSTRACT

OMEGA-3 FATTY ACIDS AND DEPRESSIVE SYMPTOMOLOGY AND THE INFLUENCE
OF PSYCHOSOCIAL STRESS: THE HISPANIC COMMUNITY HEALTH STUDY/STUDY
OF LATINOS
by
Caitlin M. Porter, RDN, LD
University of New Hampshire

Objectives: The literature on omega-3 fatty acid (FA) intake and depressive symptoms is
inconsistent, potentially due in part to the influence of psychosocial stress. Some evidence
supports that omega-3 FA intake may have greater benefit on depressive symptoms among
individuals with high oxidative stress. We quantified the associations between dietary and
plasma omega-3 FA and 6-y depressive symptoms and measured the modifying effect of
psychosocial stress.
Methods: Data are from the Hispanic Community Health Study/Study of Latinos (age 48 y, 63%
female). At baseline (2008-11), EPA, DHA and omega-3 very-long-chain FAs (VLCFAs) were
estimated using two 24-hr recalls and the NCI method. Plasma omega-3 FAs were measured by
mass spectrometry. Depressive symptoms were ascertained at baseline and 6-y follow-up with
the 10-item Center for Epidemiological Studies Depression Scale (CES-D). Approximately 9
months from baseline, the 10-item Perceived Stress (PSS) and Chronic Burden of Stress scales
x

were obtained. Unstratified and psychosocial stress-stratified associations were analyzed using
survey linear regression among those with dietary (n=3537) and plasma (n=718) FA data. Model
covariates included, but were not limited to, baseline CES-D score, Hispanic/Latino background,
study site, antidepressant use, total energy intake, and dietary or plasma omega-6 FA.
Results: Baseline DHA and omega-3 VLCFA intake were inversely associated with 6-y CES-D
(P<0.05). All examined dietary omega-3 FA exposures were inversely associated with CES-D
among individuals in the highest PSS quartile (Q4) (P<0.05), but this was attenuated after
considering omega-6 FA intake. DHA and omega-3 VLCFA intakes were inversely associated
with CES-D among individuals with 2 chronic stressors, but not <1 or >2 stressors. Plasma
omega-3 FAs were not associated with CES-D in PSS stratified and unstratified analyses.
However, plasma omega-3 FA were associated with lower CES-D score among those with only
2 chronic stressors.
Conclusions: Dietary omega-3 VLCFAs, but not plasma, were inversely associated with 6-y
CES-D. Psychosocial stress did not clearly modify these associations. These results provide
some evidence that greater omega-3 VLCFA intake may reduce depressive symptoms among
Hispanic/Latino adults. However, considering the limitations of self-reported intake, further
research is needed using biomarkers of long-term omega-3 consumption and psychosocial stress
to confirm our findings.

xi

CHAPTER I: INTRODUCTION
Rationale
Depression is a multi-factorial, debilitating disease that affects approximately 7.1% of American
adults (1) and 4.4% of adults globally (2). Depression accounts for almost 400 million lost work
days each year in the United States (3), and is the leading cause of disability worldwide (2). The
economic cost of medical treatment related to major depressive disorder in the United States
reached nearly $28 billion in 2010 (3). Hispanic/Latino Americans are one of the fastest growing
ethnic groups in the United States and it is projected that by 2060, the Hispanic/Latino
population will increase by 61.5 million people, an increase of approximately 67% (4). It has
been reported that Hispanic/Latinos are disproportionately affected by depression (5).
Hispanic/Latinos have been shown to have more depressive symptoms than other ethnic groups,
with the recent data from the Multiethnic Study of Atherosclerosis indicating that 28.2% and
13% of Hispanic/Latino women and men, respectively, experience moderate-severe depressive
symptoms compared to 11.4% - 14.7% and 4.7% -7.6% of women and men, respectively, from
other ethnic groups including non-Hispanic Whites, non-Hispanic Blacks, and Chinese (6).

Although depression is multifactorial (7), increasing evidence has linked dietary pattern quality
to incidence of depression and depressive symptoms (8,9). High diet quality has been associated
with lower risk of depression, as well as poor diet quality associated with greater risk of
depression (9). Dietary patterns have also been shown to have an independent effect on severity
of depressive symptoms, with poor diet quality resulting in increased depressive symptom
1

severity (8). It has been proposed that cardiometabolic risk factors, such as oxidative stress (10),
may increase depression incidence, as cardiovascular disease (CVD) and depression are frequent
comorbidities (11). High oxidative stress and psychological stress are known risk factors for the
development of depression and depressive symptoms (12). It has been proposed that
psychological stress may increase depression risk because psychological stress has been shown
to increase oxidative stress in humans and animal models (12,13).

Omega-3 fatty acids (FAs) have been shown in some studies to be associated with less
depressive symptoms (14), however the epidemiological evidence has been inconsistent (15),
potentially due in part to the modifying effect of oxidative stress. A handful of studies have
found a significant modifying effect of oxidative stress, as indicated by smoking status (16,17)
and lipid peroxidation (18). Additionally, it was recently found in a cohort of Puerto Rican adults
that omega-3 FA status was not associated with depressive symptoms, except in those with high
levels of oxidative stress (5), furthering the argument that the antioxidant effect of omega-3 FAs
(19) may be an important factor in their effect on reducing depressive symptoms.

Therefore, to continue to move the literature forward we quantified the association between
dietary omega-3 FA and omega-3 FA status with self-reported depressive symptoms in a large
cohort of Hispanic/Latino adults living in the U.S. Additionally, we evaluated the modifying
effects of psychological stress on these associations, to ascertain those who may experience the
most benefit of increasing omega-3 FA consumption on depressive symptoms.

2

Objectives
Aim 1: Quantify the 6-year longitudinal associations of baseline omega-3 FA consumption with
6-year depressive symptomatology and measure the modifying effect of psychological stress
among adults in HCHS/SOL. We used omega-3 FA consumption estimated by the National
Cancer Institute (NCI) method applied to two 24-hr recalls. Psychological stress was measured
using the 10-item Perceived Stress Scale (PSS-10) and Chronic Burden of Stress (CBS) scores
obtained within 9 months of the baseline study visit, most of which (73%) were completed
within 4 months from baseline. We tested whether PSS-10 and CBS each modify the prospective
associations between omega-3 FA consumption and CES-D scores. We hypothesized that higher
omega-3 FA intake would be associated with lower 6-y depressive symptomatology, and the
associations would be modified by PSS-10 and CBS scores.

Aim 2: Quantify the 6-year longitudinal associations of baseline circulating omega-3 FA levels
with depressive symptomatology and measure the modifying effect of psychological stress among
adults in HCHS/SOL. We used baseline plasma omega-3 FA levels generated from untargeted
metabolomics as a biomarker of omega-3 FA consumption. Similar to the Aim 1 approach, we
examined the associations of baseline omega-3 FA biological levels with 6-y CES-D scores.
Further, effect modification of these associations by PSS-10 and CBS scores was determined.
We hypothesized that higher plasma omega-3 FA levels would be associated with lower 6-y
depressive symptomatology, and the associations would be modified by PSS-10 and CBS scores.
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Public Health Relevance
Depression is a costly, chronic disease. Approximately 7.1% of American adults (1) and 4.4% of
adults worldwide (2) are affected by depression. Depression is costly in that it is the leading
cause of disability worldwide, and accounts for 400 million lost work days each year in the
United States alone (2). Further, the economic cost of treating major depressive disorder in the
United States reached nearly $28 billion in 2010 (3). Although depression is multifactorial and
has many risk factors and etiologies, evidence has shown an association between dietary pattern
quality and incidence of depression (9). A healthy diet pattern high in fruits, vegetables, whole
grains, olive oil, fish, soy, poultry, and low-fat dairy is associated with lower risk of depression,
while an unhealthy, Western-style, diet pattern high in red and processed meat, refined grains,
high fat dairy, butter, potatoes, and sweets and low in fruits and vegetables is associated with
greater risk of depression (9). Dietary patterns have also been shown to have an independent
effect on severity of depressive symptoms (8). Low diet quality, assessed by the Alternative
Healthy Eating Index (AHEI) score, which includes eight diet components: fruit, vegetables, nuts
and legumes, ratio of white meat to red meat, trans fat, ratio of polyunsaturated fat (PUFA) to
saturated fat, and alcohol, was associated with greater severity of depressive symptoms (8). In
addition, higher omega-3 FA intake has been shown in some, but not all, epidemiological studies
to be associated with less depressive symptoms (17,20–26).

Dietary Omega-3 FA and Depression
Much attention has been given to omega-3 FAs as they pertain to CVD. This is in part due to
their known benefits on inflammation and oxidative stress. Omega-3 FAs exert their antiinflammatory effects by decreasing activity of pro-inflammatory processes including the
4

metabolism of omega-6 FAs, leukocyte chemotaxis, adhesion molecule activity, and nuclear
factor-κB (NF-κB) activation (27). Omega-3 FAs also serve as precursors for anti-inflammatory
molecules, such as resolvins and protectins (28). Omega-3 FAs may reduce oxidative stress by
attenuating oxidative processes such as lipid peroxidation (29) and reactive oxygen species
(ROS) generation (30). Attention has been drawn to their potential benefits on depression, as
inflammation (31), oxidative stress (32) and CVD (33) are implicated in the development of
depressive symptomatology. However, there are inconsistencies (16,34–38) within the literature
with regards to the associations of omega-3 FA consumption and depressive symptoms.

The association between omega-3 FAs and depression has been studied in cross-sectional
(17,25,26), longitudinal (38–40), and case-control (41–43) studies as well as in randomized
controlled trials (RCTs) (44–46). Although a recent meta-analysis of cross-sectional and
prospective studies concluded a protective association of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) consumption, as well as total omega-3 FA intake on depressive
symptomatology there was heterogeneity across the studies examined which impedes our ability
to draw firm conclusions. For example, although EPA + DHA consumption demonstrated a
protective association in the meta-analysis, only 5 studies were examined and of these 3 were
cross-sectional (22,23,47). Further, one study examined post-partum depression (37), whereas
others were conducted among pregnant women (47) and adolescents (23). Most of these studies
independently did not report a significant protective association (23,35,37) and the study with the
strongest reported association was conducted among 70-90 year olds (22). For total omega-3 FA
intake, there was an overall significant inverse association between total omega-3 FA intake and
depression when results were pooled together. However, only 6 studies were examined, and
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among them only 2 independently found a significant association (25,26). Grosso et al. (14) also
concluded that there was heterogeneity across the studies, mainly in terms of design, population,
and omega-3 FA consumption. While some epidemiological studies support a protective
association between omega-3 FA consumption and depressive symptoms, the most recent metaanalysis of RCTs found no effect of omega-3 FAs on depressive symptoms among those without
depression, but did find a beneficial effect among participants who presented with depression at
baseline (48).

Circulating Omega-3 FA and Depression
Some studies have examined the association of omega-3 FA status and depressive
symptomatology or risk of depression (5,49,50). Biomarkers of omega-3 FA provide an
objective measure of omega-3 FA consumption as humans lack the enzyme to synthesize de
novo omega-3 FAs and thus may provide a more reliable measure of omega-3 FA exposure as
compared to dietary measures. Similar to dietary omega-3 FA, the current literature on omega-3
FA status as it relates to depression or depressive symptoms is inconsistent. Case control studies
have demonstrated that circulating levels of omega-3 FA tend to be lower in cases with
depression as compared to non-depressed controls (43,51–54). However, there are inconsistent
findings as to which omega-3 FAs most strongly relate to depression, as studies have found
differential support for total omega-3 FA (43,51,53,54), EPA (54), DHA (43,51,53,54), EPA +
DHA (43), and ALA (49). Some cohort studies have been conducted cross-sectionally or
prospectively using biomarkers of omega-3 FA status as it relates to depressive symptoms.
Results from cohort studies are inconsistent, with cross-sectional studies finding inverse (55–57),
non-linear (56,58), positive (58), and null (17,50,59) associations between omega-3 FA status
6

and depressive symptoms. A limited number of studies have looked at omega-3 FA status and
depressive symptoms longitudinally (5,59). One study conducted among older Puerto Rican
adults found that the 2-y prospective association of erythrocyte EPA and DHA with depressive
symptoms was modified by oxidative stress level (5). Among those with the highest oxidative
stress level (top quartile of urinary 8-hydroxy-2’-deoxyguanosine), greater EPA and DHA
concentrations were associated with lower 2-y depressive symptoms adjusted for baseline
depressive symptoms. Another study did not observe significant associations with depressive
symptoms when examining erythrocyte total omega-3 FA, EPA, DHA, and EPA+DHA at
baseline or 7.5 year follow up in a cohort of post-menopausal women (59). Given that there are a
limited number of studies examining omega-3 FA status and depressive symptoms prospectively,
as well as inconsistent associations in cross-sectional studies, more research is needed to
elucidate the relationship using this objective measure of omega-3 FA intake.

Psychological Stress, Oxidative Stress, and Depression
Chronic psychological stress is a well-established risk factor for depression (60). Chronic
psychological stress has been associated with increased oxidative stress, and it has been
established that oxidative stress is related to increased depressive symptomatology (61,62).
Therefore, it has been proposed that oxidative stress may serve as the link between psychological
stress and depressive symptomatology (12). The brain is particularly vulnerable to oxidative
damage, as it is metabolically active and has fewer antioxidant defenses than other tissues (63).
Psychological stress may influence depressive symptomatology by increasing oxidative stress
which can impair neuronal signaling, contribute to neurodegeneration, and increase
neuroinflammation (63). For example, it has been shown that oxidative stress can lead to the
7

activation of the enzyme indoleamine dioxygenase (IDO), which catabolizes tryptophan (64).
The activation of IDO is thought to play a role in depression, as it lowers circulating tryptophan,
and subsequently serotonin, as well as produces neurotoxic TRYCATs (tryptophan catabolites
along the IDO pathway) (64).

In an aforementioned prospective cohort study, our lab observed that greater omega-3 FA
erythrocyte concentrations were associated with lower depressive symptomatology only among
those with high oxidative stress levels (5). These result suggest that the association between
omega-3 FA consumption and depression may be modified by oxidative stress level and perhaps
by psychological stress. This may in part explain the inconsistent associations between omega-3
FA and depressive symptomatology observed in observational studies, as oxidative and
psychological stress have not been widely-considered as potential effect modifiers. In a
secondary data analysis of an omega-3 FA supplementation trial, those with high baseline lipid
peroxidation, a marker of oxidative stress, experienced a greater reduction in depressive
symptoms as compared to those with less oxidative stress at baseline (18). More recently, two
observational epidemiological studies which examined the association between omega-3 FA
consumption and depressive symptomatology stratified their analyses by smoking status (16,17),
which is a well-established pro-oxidant (65). Both studies identified significant effect
modification by smoking status, when stratifying the association of omega-3 FA or fish
consumption with depressive symptomatology by smoking status (16,17). One study in pregnant
women found an inverse relationship between EPA + DHA intake and depressive symptoms that
became significant when looking at current smokers (16). While another study found that women
who were non-smokers and high fish consumers had higher risk of depression, and men who
8

were occasional or former smokers and high fish consumers had lower risk of depression (17).
Of the few data available, oxidative stress may be a significant modifier of the association
between omega-3 FA consumption and depressive symptomatology. Considering the impact of
psychological stress on oxidative stress burden, it is possible that psychological stress may
modify the associations between omega-3 FA and depressive symptoms. However, based on our
search of the literature, no study to date has explicitly examined the impact of psychological
stress on this association in humans. One study performed in rats observed that omega-3 FA
supplementation reduced depressive symptoms in rats exposed to chronic stress (66). To move
the literature forward, this project aimed to address this knowledge gap.

Omega-3 FA Intake, Stress, and Depression in Hispanic/Latino Populations
Some evidence suggests that Hispanic/Latino populations are disproportionately affected by
psychological stress (67) and depression (68). Hispanic/Latino populations may experience a
disproportionate amount of psychological stress for a multitude of reasons including
acculturation, low socioeconomic status, and limited access to resources (69). Recently, the
Multiethnic Study of Atherosclerosis showed that more Hispanic/Latinos report moderate to high
depressive symptoms as compared to other ethnic groups, at 28.2% and 13% of Hispanic/Latino
women and men, respectively, compared to 11.4% - 14.7% and 4.7% -7.6% of women and men,
respectively, from other ethnic groups including non-Hispanic whites, non-Hispanic blacks, and
Chinese (6). The high burden of depression may in part be due to suboptimal consumption of
food sources of omega-3 FAs in concert with high oxidative stress. In the Hispanic Community
Health Study, average intake of fish among Hispanic/Latino American adults was approximately
0.7 ounces per day (70), which equates to less than 5 ounces per week. The current 2015-2020
9

Dietary Guidelines for Americans recommend that Americans consume approximately 8 ounces
of fish or seafood per week based on a 2,000 calorie diet for general health (71). This
recommendation equates to approximately 250 mg per day of combined DHA and EPA (71).
Further, Mexican-Americans have been shown to have lower long chain omega-3 FA intakes as
compared to non-Hispanic/Latino Whites and non-Hispanic/Latino Blacks, with mean intakes
from food and supplements of 0.17, 0.22, and 0.19 g/day, respectively (72). Given the evidence
of low omega-3 FA consumption and high depressive and stress burden, it is critical to better
clarify the interrelationship between omega-3 FAs, stress, and depressive mood among
individuals of Hispanic/Latino descent. Examining these associations could have significant
implications for the treatment and prevention of depression, a debilitating and costly disease.

Current Literature Gaps and Future Directions
Currently, there are gaps within the literature that need to be addressed and more research needs
to be completed in order to determine the modifying effect of psychological stress on the
association between omega-3 FA and depressive symptoms. Lack of consideration for the
potential modifying effect of psychological stress may help to explain the inconsistencies in the
current literature, which to our knowledge has not been investigated. Further, there has been
limited use of objective measures of omega-3 FA intake, which may strengthen the results. The
results from this thesis project provide additional evidence that my help to identify populations
that may most benefit from omega-3 consumption for the reduction in depressive
symptomatology. While depression is multifactorial and does not have one specific etiology,
dietary practices may provide significant benefits in terms of symptom reduction.

10

CHAPTER II: METHODS
Participants
Participants were from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), a
population-based prospective cohort study. Data were collected in the first wave of HCHS/SOL
between 2008 and 2011 from 16,415 self-identified Hispanic/Latino adults aged 18-76 years,
recruited from four different field centers (Bronx, NY, Chicago, IL, Miami, FL, and San Diego,
CA) (69,73). The 45-74 year age group was oversampled to ascertain chronic disease rates (74).
Data were collected in the second wave of HCHS/SOL between 2014 and 2017 (n = 11,623).

Of the 16,415 participants in the first wave of HCHS/SOL, 7,321 (45%) were eligible to
participate in the Sociocultural Ancillary Study (SCAS) by consenting to future contact and
being willing to participate (69) (Figure 1). The SCAS was a cross-sectional ancillary study that
investigated the associations of social, cultural, and psychological factors with metabolic
syndrome, CVD, and their risk factors within HCHS/SOL (69). Data from 5,313 (32% of
baseline cohort) participants were collected in the SCAS (69) within 9 months of their baseline
HCHS/SOL visit between February 2010 and June 2011 (69). Detailed methods for HCHS/SOL
and SCAS have been described elsewhere (69,74,76). SCAS collected measures of psychosocial
stress including the 10-item Perceived Stress Scale (PSS-10) and 8-item Chronic Burden of
Stress. In addition, of the HCHS/SOL baseline cohort, approximately 25-33% of participants
participated in the SOL Whole Genome Sequencing (WGS) and Metabolomics Ancillary Study.
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Data from WGS and Metabolomics Ancillary Study include metabolomic measures of plasma
omega-3 FAs.

3,896 participants had complete covariate data and participated in both the second wave of
HCHS/SOL and SCAS. Further exclusions were applied to individuals missing outcome or effect
modifier data: 10-item Center for Epidemiological Studies-Depression Scale (CES-D) score at
baseline (n=33) and 6-y follow up CES-D (n=89), PSS-10 (n=71), and Chronic Burden of Stress
(n=203). No additional exclusions were necessary for missing exposure data, as missing dietary
data were captured when excluding missing covariate data. A final sample of n=3,537 was
available for prospective analyses with dietary omega-3 FAs as the exposure (Figure 1). For
metabolomic analyses, additional exclusions were applied for those missing metabolomic
measures of circulating omega-3 FA (n=2,556). A final sample of n=718 was available for
prospective analyses with metabolomic omega-3 FAs as the exposure (Figure 1).

Primary Exposure: Dietary omega-3 FAs
Participants completed two 24-hour dietary recalls during the first wave of HCHS/SOL (20082011). The first 24-hour dietary recall was completed in person during the baseline visit (77).
The second 24-hour dietary recall was administered over the telephone within 6 weeks of the
baseline visit (74,77). Nutrients were analyzed using the Nutrition Data System for Research
(NDS-R) (version 11, University of Minnesota, Minneapolis, MN) (70). Further nutrient analysis
was conducted using the National Cancer Institute (NCI) Method, a statistical model to estimate
usual intake of episodically consumed foods (78). The NCI method estimates an individual’s
12

usual intake of foods and nutrients accounting for sampling weight and adjusting for covariates
including: age, sex, Hispanic/Latino background, HCHS/SOL center, day of the week, first or
second recall, and self-report of intake being greater, same, or less than usual, and. Omega-3 FAs
were expressed as percent of total FA intake (saturated, monounsaturated, polyunsaturated and
trans FAs). Omega-3 FAs were analyzed as EPA, DHA, and very-long-chain omega-3 FAs
(omega-3 VLCFA). Omega-3 VLCFA is the sum of EPA, docosapentaenoic acid (DPA) and
DHA. These were grouped together for analyses as they represent animal-derived omega-3 FAs
(e.g., fatty fish) (79). It has been previously supported that fish intake is inversely associated
with depression, therefore it is of importance to analyze omega-3 VLCFAs separately (80).
Dietary omega-3 FAs were analyzed continuously.

Secondary Exposure: Circulating omega-3 FAs
Participants had a fasting blood draw during their baseline exam (81). Plasma was collected in
EDTA anticoagulated tubes and centrifuged at 3000 x g at 15°C for 30 minutes (81). Aliquots
were frozen at -80°C at the field centers and sent to the central laboratory at the University of
Minnesota for biomarker analysis (81). Plasma metabolites were measured by Metabolon, Inc
(Morrisville, NC) using untargeted mass spec-based metabolomics profiling. This method
incorporates two separate ultra-high performance liquid chromatography/tandem mass
spectrometry injections and one gas chromatography/mass spectrometry injection per sample,
and can detect metabolites in the range of low nanograms per milliliter (82). Circulating omega-3
FAs were expressed as percent of total circulating FAs (saturated, monounsaturated,
polyunsaturated, and trans FAs). Circulating omega-3 FAs were analyzed continuously as EPA,
DHA and omega-3 VLCFAs as the sum of EPA, DPA, and DHA.
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Primary Outcome: 6-year depressive symptomatology
Self-reported depressive symptoms were assessed using the 10-item Center for Epidemiological
Studies Depression Scale (CES-D) during the baseline exam and approximate 6-year follow up.
CES-D is an abridged version of the 20-item CES-D scale that assesses depressive
symptomatology over the past week using a score ranging from 0-30, with a higher score
indicating more depressive symptoms (83). CES-D was offered in the participant’s preferred
language, and was shown to measure the same construct in the English and Spanish versions in
HCHS/SOL participants (84). A cut-point of 10 on the CES-D indicates high depressive
symptoms with both sensitivity and specificity (85) to the validated cut-off of ≥16 on the 20-item
CES-D (86). CES-D was analyzed continuously.

Psychological Stress: Perceived Stress Scale and Chronic Burden of Stress
Self-reported psychological stress was measured via the 10-item Perceived Stress Scale (PSS-10)
(87) and 8-item Chronic Burden of Stress scale (88,89) as part of the SCAS. Questionnaires were
administered by a trained interviewer within 9 months of the HCHS/SOL baseline exam (75),
most (73%) were completed within 4 months (75).

PSS-10 is a 10-item questionnaire which assesses the individual's reaction to and ability to cope
with stressors over the past month (87). PSS-10 responses are on a Likert scale of 0-4 (never to
very often). PSS-10 responses are added together, with questions 4, 5, 7, and 8 reverse scored.
Possible PSS-10 scores range from 0-40, with a higher score indicating more perceived stress

14

(77). There is no pre-determined cutoff for PSS-10 (90), therefore we categorized PSS-10 scores
into quartiles, as has been done in previously in HCHS/SOL (6).

The Chronic Burden of Stress scale measures chronic stress over the past 6 months in 8 domains
(personal health, health problems in family members, substance abuse in family members,
financial stress, occupational stress, stress related to housing, relationship stress and caregiving
stress) (77). This measure of chronic stress has been used in other multi-ethnic studies (92,93)
and other Hispanic/Latino American populations (94). Chronic Burden of Stress counts the
number of chronic stressors someone has experienced over the past 6 months or more, ranging
from 0-8 (77). A chronic stressor was indicated by the participant identifying a problem as
ongoing for 6 months or more, and found to be moderately to severely stressful (89). We
categorized number of chronic stressors as 0, 1, 2, or ≥3, as has been done previously in
HCHS/SOL (77).

PSS-10 and Chronic Burden of Stress have both been associated with chronic disease burden
(75,95). In the current study we utilized both measures, as PSS-10 captures more recent stressors
(past 30 days) and Chronic Burden of Stress captures longer-term stressors (past 6 months). Both
Chronic Burden of Stress and PSS-10 have been associated with high depressive symptoms
(CES-D ≥10) in HCHS/SOL (77). In relation to dietary intake, both PSS-10 and Chronic Burden
of Stress were associated with significantly higher energy intake in HCHS/SOL (77), while only
PSS-10 was associated with significantly lower AHEI-2010 score (77). HCHS/SOL participants
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with obesity reported a greater number of chronic stressors than those who were normal or
overweight (77).

Covariates
Demographic covariates
Models were adjusted for a number of covariates that may influence the associations of dietary
and circulating omega-3 FAs and depression including total energy (25,96), sex (97,98), age
(83,97), smoking status (5,99), physical activity (100,101), education level (102,103), history of
CVD (83,104) or diabetes (105,106), marital status (83,107), household income (98,100) and
Hispanic/Latino background (83,108). Demographic characteristics were self-reported during the
baseline visit including sex, age, smoking status, physical activity, education level, marital status,
household income and Hispanic/Latino background. Covariates are defined similarly to previous
HCHS/SOL studies. Smoking status was defined as those currently smoking at baseline (yes or
no) (5). Physical activity was defined as number of MET-mins per week based on self-reported
responses to the Global Physical Activity Questionnaire. Education level was defined as less than
high school, high school or equivalent, or greater than high school (83). Marital status was
defined as married or living with a partner, single and divorced or widowed (83). Household
income was reported dichotomously as ≤$30,000 per year or >$30,000 per year (75).
Hispanic/Latino background was self-reported as Dominican, Central American, Cuban,
Mexican, Puerto Rican, South American, or more than one heritage/other.
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Clinical covariates
Clinical covariates include history of CVD and diabetes (DM). Participants were considered to
have CVD if they had electrocardiogram record of possible old MI, or self-reported history of
myocardial infarction (MI), coronary artery bypass surgery, percutaneous transluminal coronary
angioplasty, and/or stroke (83). Participants were considered to have diabetes if they selfreported history of diabetes, had a fasting blood glucose of ≥126 mg/dL, blood glucose of >200
mg/dL on the oral glucose tolerance test, or had a glycosylated hemoglobin of ≥6.5% (109).
Antidepressant use was ascertained by participants bringing all medications taken within the past
four weeks to the field center during the baseline assessment (74,83).

Dietary covariates
Dietary covariates were collected using two 24-hour recalls and estimated using the NCI method,
as described above. Dietary covariates included total energy (kcals/d), intake of fruit
(servings/d), vegetables (servings/d), and added sugar (g/d). Further, omega-6 FA consumption
and status were considered, as omega-3 FAs and omega-6 FAs share enzymatic pathways, and
compete for desaturation and elongation into the longer chain forms (110). For dietary analyses,
total omega-6 FA consumption (arachidonic acid and linoleic acid) were expressed as a
percentage total FA intake. For metabolomic analyses, total circulating omega-6 FAs (adrenate,
arachidonate, dihomolinoleate, docasdienoate, hexadecadienoate, and linoleate) were expressed
as a percentage of total circulating fatty acids.
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Statistical analysis
All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). The significance
level was set at P<0.05 for analyses and P<0.10 for effect modification testing. Data were
assessed for normality and skewness. Skewed data, baseline CES-D and 6-y CES-D, were
normalized using a Box-Cox transformation (111). Data are presented as back-transformed
means and standard errors to increase interpretability. For descriptive purposes, we examined
differences in baseline sample characteristics (covariates described above) by quartile of dietary
and circulating omega-3 VLCFA using survey linear regression in models adjusted for age and
sex accordingly.

Analyses were conducted using survey linear regression to account for the complex survey
design in HCHS/SOL. In dietary analyses, associations between baseline omega-3 FA
consumption (EPA, DHA, and omega-3 VLCFA) and 6-y CES-D were analyzed. Two models
were examined. Model 1 considered sex, age, smoking status, physical activity, education level,
marital status, household income, Hispanic/Latino background, HCHS/SOL study site,
antidepressant use, CVD status, diabetes status, baseline CES-D, time between visits, total
energy intake and consumption of fruits, vegetables, and added sugar. Model 2 was further
adjusted for dietary or circulating omega-6 FA. Analyses were stratified a priori by quartiles of
PSS-10 and number of chronic stressors (0, 1, 2, ≥3). Similar analyses were conducted using
circulating omega-3 FAs as the exposure. In a set of sensitivity analyses we excluded fish oil
supplement users. Given that our dietary omega-3 FA exposure did not include intake from
supplements, fish oil users would inherently consume additional omega-3 VLCFA that were
unaccounted for, it is estimated that fish oil supplements contain an average of 180 mg of EPA
18

and 120 mg DHA (112). In addition, supplement users are more likely to engage in healthpromoting behaviors (113) which could introduce residual confounding.
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CHAPTER III: RESULTS
Sample Characteristics
Our final analytical sample (n = 3,537) for prospective analyses using dietary omega-3 FAs as
the exposure was primarily female (63%) with a mean age of 47.6 ± 0.2 years (data not shown).
Average time between baseline and follow up visits was 5.7 ± 0.01 years. At follow up, 26% of
participants reported high depressive symptoms (CES-D ≥10) compared to 31% at baseline.

Those consuming greater amounts of omega-3 VLCFA were older, more physically active, and
had higher income (Table 1). Further, higher omega-3 VLCFA consumption was seen among
females and non-smokers. Additionally, higher omega-3 VLCFA consumption was associated
with lower PSS-10 score and use of antidepressants (p < 0.05 for all). Those consuming more
omega-3 VLCFA reported greater consumption of omega-6 FAs and fruit, as well as lower total
energy intake and lower consumption of vegetables and added sugar (p < 0.001). There were no
significant differences according to omega-3 VLCFA intake among BMI, education level,
marital status, DM or CVD status, CES-D score at baseline or 6-y, or number of chronic
stressors (Table 1).

Those with greater baseline circulating omega-3 VLCFA were more likely to have a lower BMI
and higher education, be older, Dominican, from the Bronx, NY area, and married or living with
a partner (Supplemental Table 1). Additionally, those with the highest baseline circulating
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omega-3 VLCFA were less likely to have DM or smoke and report lower perceived and chronic
stress (p < 0.05 for all, Supplemental Table 1). In terms of dietary characteristics, those with
greater baseline circulating omega-3 VLCFA reported lower total energy and added sugar intake,
and higher intakes of fruit and omega-3 VLCFA (p < 0.05 for all, Supplemental Table 1).

Associations between dietary omega-3 FAs and 6-y CES-D score
Baseline DHA and omega-3 VLCFA consumption were inversely associated with 6-y CES-D
score after adjusting for clinical, demographic, and dietary covariates (p < 0.05) (Figure 2).
These associations remained significant after adjusting for total omega-6 FA consumption (p <
0.05, Figure 2). Baseline EPA consumption tended to be inversely associated with 6-y CES-D
score (p < 0.10, Figure 2), however this association was attenuated after adjusting for total
omega-6 FA consumption.

When stratified by quartile of PSS-10 score, baseline EPA, DHA and omega-3 VLCFA
consumption were associated with lower 6-y CES-D score among those with the highest level of
perceived stress (Q4) after adjusting for demographic, clinical, and dietary covariates (p < 0.05)
(Table 2). The strongest effect size was observed with EPA (β = -1.00 ± 5.59, Table 2). Further,
EPA consumption was inversely associated with 6-y CES-D score in Q2 of perceived stress (p <
0.05, Table 2). After adjusting for total omega-6 consumption, the PSS-10-stratified associations
between DHA and omega-3 VLCFA consumption and 6-y CES-D score were attenuated (Table
2). However, the inverse association between EPA consumption and 6-y CES-D remained
significant in Q2 of PSS-10 (p < 0.05, Table 2). Interestingly, after adjusting for total omega-6
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FA consumption, DHA became significantly protective of 6-y CES-D score in Q3 of PSS-10 (p
< 0.05, Table 2).

When stratified by number of ongoing chronic stressors (≥6 months), after adjusting for
demographic, clinical, and dietary covariates we observed significant inverse associations
between both DHA and omega-3 VLCFA consumption, but not EPA, with 6-y CES-D score
among those reporting 2 chronic stressors (p < 0.05) (Table 3). Similarly, EPA trended towards
an inverse association with 6-y CES-D score among those reporting 2 chronic stressors (p < 0.10,
Table 3). After adjusting for total omega-6 consumption, the inverse associations between DHA
and omega-3 VLCFA consumption with 6-y CES-D remained significant (p < 0.05, Table 3) and
EPA remained trending towards significance (p < 0.10, Table 3). We did not observe any
significant associations with any dietary omega-3 FA in any model among those reporting 0, 1,
or ≥3 chronic stressors (Table 3).

Associations between circulating omega-3 FAs and 6-y CES-D score
Baseline circulating EPA, DHA, and omega-3 VLCFA were not associated with 6-y CES-D
score after adjusting for clinical, demographic, and dietary covariates (Figure 3). These
associations remained non-significant after adjusting for circulating total omega-6 FA (Figure 3).

When stratified by quartile of PSS-10 score, circulating EPA, DHA, and omega-3 VLCFA were
not associated with 6-y CES-D score at any level of perceived stress after adjusting for clinical,
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demographic, and dietary covariates (Table 4). These associations remained non-significant at
all levels of perceived stress after adjusting for circulating total omega-6 FAs (Table 4).

When stratified by number of chronic stressors, circulating EPA, DHA, and omega-3 VLCFA
were inversely associated with 6-y CES-D score among those reporting 2 chronic stressors after
adjusting for clinical, demographic, and dietary covariates (p < 0.01) (Table 5). The strongest
effect size was observed with DHA (β = -0.99 ± 0.62, Table 5). EPA trended towards an inverse
association among those reporting ≥3 chronic stressors (p < 0.10, Table 5). After adjusting for
circulating total omega-6 FAs, the associations of circulating EPA, DHA, and omega-3 VLCFA
with 6-y CES-D remained significant among those reporting 2 chronic stressors (p < 0.01, Table
5) and EPA remained trending towards an inverse association among those with ≥3 chronic
stressors (p < 0.10, Table 5). DHA and omega-3 VLCFA were not associated with 6-y CES-D
score among those reporting 0, 1, or ≥3 chronic stressors in either model (Table 3). EPA was not
associated with 6-y CES-D among those reporting 0 or 1 chronic stressor in either model (Table
3).

Sensitivity Analyses
Sensitivity analyses were conducted excluding fish oil supplement users (n = 272, 8% for dietary
analyses; n = 48, 7% for circulating analyses). After excluding those who reported using fish oil
supplements, unstratified analyses of dietary omega-3 FAs with 6-y CES-D score remained
unchanged, as consumption of DHA and omega-3 VLCFA were inversely associated with 6-y
CES-D score in both Model 1 and Model 2 (p <0.05) (Supplementary Table 2). When stratified
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by quartile of PSS-10 score, EPA became positively associated with 6-y CES-D score among
those in Q1 in both models (p <0.05, Supplementary Table 2). Further, EPA remained inversely
associated with 6-y CES-D score among those in Q2 in Model 1, however the association was
attenuated after adjusting for total omega-6 FA consumption (p >0.05, Supplementary Table 2).
Additionally, EPA was no longer inversely associated with 6-y CES-D in Q4 in Model 1. Similar
to our primary findings, DHA and omega-3 VLCFA were inversely associated with 6-y CES-D
in Q4 in Model 1, but the associations were attenuated after adjusting for omega-6 FA
consumption. DHA consumption was now significantly inversely associated with 6-y CES-D in
Q3 in Model 1 and Model 2, whereas in our main findings DHA was only inversely associated
with 6-y CES-D in Q3 of Model 2 (p <0.05, Supplementary Table 2). When stratified by chronic
stress, dietary omega-3 VLCFA were no longer associated with 6-y CES-D among those
reporting 2 chronic stressors in Model 1, however the association was significant after adjusting
for total omega-6 FA consumption, similar to our primary findings. There were no changes in
any other dietary omega-3 FA by level of chronic stress. For circulating omega-3 FAs, there
were no changes in our results after excluding fish oil consumers (Supplementary Table 3).
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CHAPTER IV: DISCUSSION
Among a cohort of Hispanic/Latino adults, we observed inverse associations between DHA and
omega-3 VLCFA consumption with 6-y depressive symptoms after adjusting for baseline
depressive symptoms and demographic, clinical, and dietary covariates. These results remained
significant after accounting for total omega-6 FA consumption. When considering psychosocial
stress, EPA, DHA, and omega-3 VLCFA consumption were inversely associated with 6-y
depressive symptoms among those with the highest (Q4) perceived stress. However, these
associations were attenuated after accounting for omega-6 FA consumption. When considering a
longer-term measure of stress (past 6 months), DHA and omega-3 VLCFA consumption were
inversely associated with 6-y depressive symptoms among those who reported experiencing 2
chronic stressors. These associations remained significant after accounting for total omega-6 FA
intake. We observed null associations between circulating omega-3 FA and 6-y depressive
symptoms in this cohort in unstratified analyses or at any level of perceived stress. However,
similarly to our dietary analyses, there were protective associations on 6-y depressive symptoms
with circulating EPA, DHA, and omega-3 VLCFA among those who reported 2 chronic
stressors, regardless of total omega-6 FA status. To the best of our knowledge, this is the first
study to examine the associations between omega-3 FA and depressive symptoms according to
level of psychological stress.
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Unstratified associations between dietary and plasma omega-3 FA with 6-y depressive
symptoms
We observed protective associations of DHA and omega-3 VLCFA consumption on 6-y
depressive symptoms. Previous literature supports inverse associations between omega-3 FA
intake and depressive symptoms (55–57). However, the bulk of the literature pertaining to
omega-3 FA consumption and depressive symptoms is cross-sectional, therefore interpretations
may be hindered by reverse causality. Our findings help to strengthen this body of literature by
using a prospective design. Among previous research that has examined these associations
longitudinally, the majority found null associations (25,114–116). However, a recent metaanalysis of observational studies found an overall pooled effect of EPA+DHA consumption with
a lower risk of depression (RR 0.78 95% CI: 0.67, 0.92) (14). In a sub-analysis, a stronger
relationship between EPA+DHA consumption and depression was found in longitudinal studies
versus cross-sectional (14). We found DHA consumption, but not EPA, to be protective of 6-y
depressive symptoms. In a sub-analysis in the aforementioned meta-analysis of observational
studies examining omega-3 FA consumption and depressive symptoms, a null association was
found regarding the association between DHA consumption alone and depressive symptoms
(14). However, in a study of Greek adults, DHA in the adipose tissue was inversely associated
with depressive symptoms in cross-sectional analyses (117). Although EPA is typically
considered to be more beneficial than DHA on reducing depressive symptoms, as has been
supported by meta-analyses of RCTs (48,118), doses of EPA in RCTs ranged from 0.63 - 6.2 g/d
(48), whereas consumption in our sample ranged from 0.008 – 0.12 g/d EPA, which likely
limited our ability to detect an effect.
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We did not observe an association between circulating omega-3 FA and 6-y depressive
symptoms. Consistent with our findings, some studies show that there is no association between
omega-3 FA status and depressive symptoms longitudinally (5,119). However, one study sample
had a low rate of high baseline depressive symptoms at 8% (119), and another had a relatively
short follow up of 2 years (5), which may have contributed to finding null associations.
Conversely, a cross-sectional study among Greek adults found that plasma omega-3 FAs were
inversely associated with depressive symptoms (55). However, this sample had considerably
higher levels of circulating omega-3 FA compared to our sample. Therefore, low circulating
levels in our sample may have limited our ability to detect an association. Further, we used
plasma levels of omega-3 FAs to determine omega-3 status, which is indicative of omega-3 FA
consumption over a short period (days to weeks) (120). Research using biochemical measures of
longer-term intake, such as red blood cells or adipose tissue (120) is warranted. Additionally, our
sample size for analyses using circulating omega-3 FA was considerably smaller than our sample
for dietary analyses, which may have weakened our power to detect an association.

Associations between dietary omega-3 FA and 6-y depressive symptoms stratified by
quartiles of PSS-10
In agreement with our hypothesis, dietary DHA and omega-3 VLCFA were inversely associated
with depressive symptoms among those experiencing the highest perceived stress (Q4). There is
evidence to support that perceived stress is associated with greater levels of markers for
inflammation (121) and oxidative stress (122). Therefore, these findings are supported by
previous studies that have found the anti-depressant effects of omega-3 FAs to be enhanced
among those with higher levels of oxidative stress (5,18). Similar to our findings, a sub-analysis
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of one study among Puerto Rican adults found that erythrocyte DHA, not EPA, was significantly
protective of 2-y depressive symptoms among those with the highest oxidative stress (5). It is
possible that the different metabolites of EPA and DHA may provide unique physiological
benefits. For example, the DHA-derived metabolite, neuroprotectin D1, may protect the brain
from oxidative damage (123), as evidenced by neuronal cell culture and animal model studies
(124,125).

We observed attenuation of the protective associations of EPA, DHA, and omega-3 VLCFA
consumption on 6-y depressive symptoms after adjusting for total omega-6 FA consumption.
The aforementioned epidemiological studies examining the modifying effect of oxidative stress
on the association between omega-3 FA and depressive symptoms did not account for omega-6
FA status or consumption, which impedes our ability to elucidate if this is a unique finding. Our
consideration of omega-6 FAs is novel and will help to expand this field of literature. However, a
secondary analysis of an RCT found a greater benefit of omega-3 FA supplementation on
depressive symptoms among those with high baseline lipid peroxidation, supporting that the
beneficial effects were attributable to omega-3 FAs (18). Given that omega-3 FA and omega-6
FA compete for elongation and desaturation by sharing enzymatic pathways, higher consumption
of omega-6 FA reduces the metabolism of omega-3 FA into the longer chain forms (110). The
handful of epidemiological studies that adjusted for omega-6 FA consumption when analyzing
the associations between omega-3 FA and depressive symptoms have mixed findings (25,35).
Although commonly thought to be pro-inflammatory, there is evidence that some eicosanoids
produced from arachidonic acid, such as prostaglandin E2 and lipoxin A4, may have antiinflammatory properties (126,127). However, there is evidence to support that patients with
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major depressive disorder have greater plasma omega-6 FAs compared to non-depressed controls
(129) and that omega-6 FA consumption is positively associated with depressive symptoms
(130). More longitudinal studies using objective markers of omega-3 FA and omega-6 FA are
needed to clarify the relationship between omega-3 FAs, omega-6 FAs, and depressive
symptoms.

Associations between dietary and circulating omega-3 FA stratified by number of chronic
stressors
In an unexpected finding, both dietary and circulating omega-3 FAs were inversely associated
with 6-y depressive symptoms among those who reported experiencing 2 chronic stressors, but
not among those with the highest chronic stress (≥3 chronic stressors) as we had hypothesized. In
HCHS/SOL, Chronic Burden of Stress has been shown to be positively associated with chronic
diseases such as DM, HTN, and CHD cross-sectionally (75), supporting Chronic Burden of
Stress as a potential predictor of pathophysiological effects of stress. Further, a shortened version
of the Chronic Burden of Stress was positively associated with interleukin (IL) 6 and C-reactive
protein in a multi-ethnic cohort (131), suggesting a positive association between this measure of
chronic stress and inflammation. To the best of our knowledge, the effect of psychological stress
on the association between omega-3 FA and depressive symptoms has yet been studied in
humans. However, in animal models omega-3 FA supplementation appears to reduce depressive
symptoms after exposure to chronic stress (132,133).
Interestingly, we observed the strongest associations between omega-3 FA status and
consumption with 6-y depressive symptoms among those who reported experiencing 2 chronic
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stressors. Those who reported experiencing 2 chronic stressors had the highest prevalence of
baseline CVD compared to those experiencing 0, 1, or ≥3 stressors (7.4% vs. 3.4-6.9%),
potentially suggesting that they had a higher overall oxidative stress load (134). Additionally,
those who were experiencing ≥3 chronic stressors had a considerably higher rate of
antidepressant medication use (12.7%) compared to those with 0, 1, or 2 stressors (3.1-5.7%).
Higher rates of antidepressant use suggests that these individuals may have more access and
utilization of health care services. Therefore, although those with ≥3 chronic stressors are
experiencing the greatest number stressors, they may have more resources to cope with stress
therefore weakening the negative physiological effects. Additionally, it is possible that those
experiencing ≥3 chronic stressors may be more resilient towards stress, and therefore have less
of a physiological response, as evidence suggests that after repeated exposure to a stressor there
can be a diminished response to future stressors of the same type (136).

Biological Plausibility
Oxidative stress, an imbalance of reactive oxygen species (ROS) production and antioxidant
activity, can contribute to onset of depressive symptoms through damage of DNA, lipids, and
proteins. Oxidative stress-induced damage of DNA and proteins is implicated in
neurodegeneration (63,137), a characteristic of depression (138,139) (Figure 4). Lipid
peroxidation as a result of oxidative stress can alter cellular membrane structure, potentially
affecting neuronal signaling (63). Treatment with antidepressant medications has been shown to
reduce oxidative stress (140,141), providing further support for the role of oxidative stress in
depression.
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Inflammation and oxidative stress are related processes, such that inflammation can induce
oxidative stress and vice versa (142) (Figure 4). This cyclical relationship occurs via several
physiological mechanisms. For example, when activated, immune cells produce ROS as a
cellular defense mechanism (143). Conversely, oxidative stress can induce inflammation via
several mechanisms. For example, ROS can activate NF-κB (144), a pro-inflammatory
transcription factor. Additionally, 8-isoprostane, a byproduct of lipid peroxidation, has been
shown to upregulate the production of IL-8, an inflammatory cytokine (145).

Inflammation is implicated in the development of depression by affecting neurotransmitter
synthesis and inducing neuroinflammation (31) (Figure 4). Inflammatory cytokines can induce
depressive symptoms by activating the IDO pathway, which diverts metabolism of tryptophan
away from serotonin production and towards production of TRYCATs (146). TRYCATs are
neurotoxic byproducts of the IDO pathway that may contribute to depressive symptoms (146). In
mice, lipopolysaccharide-induced systemic inflammation lead to neuroinflammation and
subsequent neurodegeneration (147). In humans undergoing treatment for cancer or hepatitis C
with the administration of pro-inflammatory cytokines, IL-2 and interferon-α , over one third of
patients are estimated to develop depression (148). The influence of inflammation on depressive
symptoms is further corroborated by evidence that antidepressant medications reduce
inflammation (149).
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Psychological stress can induce both oxidative stress and systemic inflammation (61,150).
Oxidative stress is hypothesized to be a physiological link between psychological stress and
depression (12). Psychological stress can lead to the activation of NF-κB (12) which promotes
both oxidative stress and inflammation by increasing production of ROS and pro-inflammatory
cytokines (151,152). Omega-3 FAs are widely recognized for exerting anti-inflammatory effects
in the body. These anti-inflammatory effects are a result of a number of physiological
mechanisms including activation of anti-inflammatory processes and mitigation of proinflammatory processes. Metabolic byproducts synthesized from EPA and DHA via
cyclooxygenase and lipoxygenase enzyme activity, including E-series resolvins, derived from
EPA, and D-series resolvins and protectins derived from DHA, are potent anti-inflammatory
mediators (28). These bioactive molecules are able to both dampen the inflammatory response
(128), as well as promote resolution of existing inflammation (28). Further, EPA and the omega6 FA arachidonic acid (ARA) can both lead to the synthesis of eicosanoids, as they each contain
a 20-carbon chain. However, while eicosanoids derived from ARA are potently proinflammatory, EPA-derived eicosanoids are estimated to be 10-100 times less inflammatory than
those from ARA (128). EPA reduces ARA-mediated inflammation by reducing the rate at which
ARA-derived eicosanoids are synthesized and leading to the synthesis of much less potent
eicosanoids. In addition, omega-3 FAs can mitigate pro-inflammatory cytokine production
(153,154) and reduce the activity of NF-κB (155). Some evidence suggests that omega-3 FAs
may mitigate oxidative stress by reducing ROS production (30) and upregulating endogenous
antioxidant activity (156). However, given the potent anti-inflammatory properties of omega-3
FAs discussed above, the omega-3 FA-induced reduction in inflammation is likely contributing
to mitigation of oxidative stress.
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Strengths and Limitations
There are several strengths to our current study. We used a prospective design, which reduces the
possibility of reverse causality that would be present in a cross-sectional design. Further, our
analytical sample size is larger than previous studies in this field. We also used an objective
measure of omega-3 FAs in conjunction with dietary measures, which may help clarify some of
the error that is inherently introduced when relying on self-reported dietary data. By using
measures of both recent (past 30 days) and chronic (past 6 months) psychological stress, we were
able to capture a wide range of stressors.

Although there are many strengths of our study, several limitations exist. Dietary intake was only
available at baseline, leading us to assume no variation in intake over the six year follow up.
Additionally, diet was measured using two 24-hour recalls, whereas the use of three 24-hour
recalls is typically recommended to improve accuracy (157,158). This discrepancy may have
contributed to misclassification errors. However, the use of the NCI method increased the
accuracy of estimating usual dietary intakes. Further, plasma omega-3 FAs are a biomarker that
is relevant to the past several days to weeks (120), and do not reflect as long of a time period as
other biomarkers of omega-3 FAs. Although we considered a number of potential confounding
variables, residual confounding is still a concern.

Conclusions
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We found that DHA and omega-3 VLCFA consumption was associated with lower 6-y
depressive symptoms in a cohort of Hispanic/Latino adults living in the US. In addition, we
found that dietary DHA and omega-3 VLCFA and plasma EPA, DHA, and omega-3 VLCFA
were inversely associated with 6-y depressive symptoms among those who reported experiencing
two chronic stressors. These findings provide support that omega-3 FA consumption may reduce
depressive symptoms in a Hispanic/Latino cohort. Future studies are needed to analyze these
associations using objective measures of omega-3 FA that are representative of longer term
intake of omega-3 FAs in longitudinal studies.
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Table 1. Sample characteristics by quartile of baseline omega-3 VLCFA consumption1
P-trend

BMI

Dietary Omega-3 VLCFA (Quartile)2
Q1
Q2
Q3
Q4
n=884
n=884
n=885
n=884
29.9 ± 0.26
29.5 ± 0.30
29.5 ± 0.25
30.2 ± 0.35

Age, years

42.4 ± 0.81

43.0 ± 0.66

42.7 ± 0.78

47.6 ± 0.93

<0.001

Female, %

49.9

53.1

60.2

63.2

<0.001

Dominican, %

1.9

4.5

10.5

27.5

<0.001

Central American, %

6.7

7.6

8.0

5.9

0.38

Cuban, %

37.41

19.32

9.67

4.32

<0.001

Mexican,%

36.6

43.7

48.7

30.9

0.06

Puerto Rican, %

14.0

18.8

15.2

16.1

0.59

South American, %

1.0

3.5

6.2

11.9

<0.001

Multiple/Other, %

2.5

2.6

1.7

3.5

0.30

Bronx, %

13.8

21.0

29.2

56.3

<0.001

Chicago, %

19.9

20.0

13.4

8.4

<0.001

Miami, %

45.0

29.2

19.3

10.7

<0.001

San Diego, %

21.2

29.8

38.1

24.6

0.54

<HS, %

26.4

31.9

29.8

34.1

0.09

HS or equivalent, %

34.2

25.1

26.4

26.2

0.37

>HS, %

39.4

43.0

43.8

39.7

0.39

Income >$30,000, %

26.6

29.8

35.5

31.8

<0.05

Single, %

33.5

31.1

31.3

28.2

0.78

Married/Living with a Partner, %

50.8

50.6

51.6

50.2

0.93

Separated/Divorced, %

15.7

18.4

17.1

21.6

0.87

Diabetes, %

15.5

18.0

16.4

20.5

0.65

Cardiovascular Disease, %

4.3

5.3

4.6

5.7

0.48

626 ± 58.4

543 ± 47.1

554 ± 34.2

741 ± 50.2

<0.05

Smoking, %

24.8

20.8

15.8

13.1

<0.001

Antidepressant use, %

6.9

5.1

6.3

3.9

<0.05

2116 ± 22

2019 ± 21

1905 ± 17

1748 ± 22

<0.001

Vegetables, servings/d

2.10 ± 0.03

2.04 ± 0.03

2.01 ± 0.03

1.89 ± 0.04

<0.001

Fruit, servings/d

1.00 ± 0.03

1.06 ± 0.03

1.18 ± 0.04

1.28 ± 0.04

<0.001

Added sugar g/d
Dietary Omega-3 VLCFA, %FA

69.0 ± 1.1
0.117 ± 0.003

69.4 ± 1.2
0.168 ± 0.003

64.8 ± 1.2
0.219 ± 0.003

56.3 ± 1.2
0.333 ± 0.004

<0.001
<0.001

Dietary EPA, %FA

0.024 ± 0.001

0.035 ± 0.001

0.047 ± 0.001

0.074 ± 0.002

<0.001

Dietary DHA, %FA

0.070 ± 0.002

0.102 ± 0.002

0.132 ± 0.002

0.195 ± 0.003

<0.001

19.2 ± 0.14

19.6 ± 0.13

19.7 ± 0.12

20.2 ± 0.13

<0.001

0.09

Hispanic/Latino Background

HCHS Site

Marital Status

Physical Activity, MET-mins/d

Energy, Kcals

Dietary Total Omega-6, %FA

35

Baseline CES-D

6.0 ± 0.1

5.5 ± 0.1

5.2 ± 0.1

5.4 ± 0.1

0.23

6-y CES-D

5.2 ± 0.1

4.9 ± 0.1

4.7 ± 0.1

4.7 ± 0.1

0.50

PSS-10 score

15.2 ± 0.3

14.7 ± 0.3

14.1 ± 0.3

13.9 ± 0.3

<0.001

Number of Chronic Stressors

1.3 ± 0.1

1.3 ± 0.1

1.2 ± 0.1

1.1 ± 0.1

0.32

1

Values are age- and sex-adjusted means ± SE or proportions by quartile of omega-3 VLCFA consumption as % total fat using proc surveyreg
and proc freq, respectively, in SAS. Q, quartile; HCHS, Hispanic Community Health Study; HS, high school education; MET, metabolic
equivalent; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; CES-D, 10-item Center for Epidemiological Studies Depression Scale;
PSS-10, 10-Item Perceived Stress Scale.
2
VLCFA, very-long-chain fatty acids, omega-3 VLCFA was calculated as the sum of EPA, DHA, and DPA.
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Table 2. Associations between baseline omega-3 FA consumption and 6-y CES-D score
stratified by quartile of PSS-10 score1,2
PSS-10 Score3
Q1

Q2

Q3

Q4

5.83 ± 0.09
n=806

12.02 ± 0.05
n=915

16.97 ± 0.05
n=930

23.71 ± 0.12
n=886

Model 1
EPA
DHA
VLCFA4

17.1 ± 5.68†
1.30 ± 1.75
0.747 ± 0.853

-0.977 ± 5.44*
-0.902 ± 1.46†
-0.729 ± 0.752†

-0.975 ± 5.91
-0.959 ± 1.79†
-0.668 ± 0.862

-0.998 ± 5.59*
-0.984 ± 1.64*
-0.851 ± 0.828*

Model 2
EPA
DHA
VLCFA4

18.6 ± 5.75†
1.45 ± 1.77
0.822 ± 0.863

-0.985 ± 5.56*
-0.884 ± 1.48
-0.709 ± 0.766†

-0.987 ± 6.80

-0.999 ± 5.59
-0.914 ± 1.62†
-0.707 ± 0.830

-0.977 ± 1.93*
-0.717 ± 0.935

Values are β ± SE estimates using multivariable survey linear regression. CES-D, 10-Item Center for Epidemiological Studies Depression
Scale; Q, Quartile; PSS-10, 10-Item Perceived Stress Scale; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; VLCFA, very long
chain omega-3 fatty acids. Omega-3 FA consumption expressed as percent of total fat intake. †P=0.05 to <0.10; *P<0.05; **P<0.01.
2
Model 1 was adjusted for sex, BMI, age, total energy intake, diabetes status, education level, smoking status, study site, physical activity,
cardiovascular disease status, marital status, Hispanic/Latino background, income, antidepressant use, baseline CES-D score, time between
visits, and intake of total energy, fruit, vegetables, and added sugar. Model 2 adjusting for Model 1 + total omega-6 FA consumption.
3
Mean ± SE PSS-10 score by quartile.
4
VLCFA calculated as the sum of EPA, DHA, and DPA (docosapentaenoic acid).
1
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Table 3. Associations between baseline omega-3 FA consumption and 6-y CES-D score
stratified by number of chronic stressors1,2
0
n=1590
Model 1
EPA
DHA
VLCFA3
Model 2
EPA
DHA
VLCFA3

Number of Chronic Stressors
1
2
n=747
n=527

3+
n=673

-0.643 ± 3.84
-0.701 ± 1.39
-0.434 ± 0.67

-0.761 ± 7.62
-0.735 ± 2.07
-0.316 ± 1.02

-0.689 ± 14.5†
-1.00 ± 3.03*
-0.944 ± 1.46*

-0.959 ± 7.27
-0.614 ± 1.85
-0.443 ± 0.916

-0.713 ± 4.16
-0.751 ± 1.52
-0.483 ± 0.73

0.832 ± 7.26
0.035 ± 1.99
0.386 ± 0.981

-0.268 ± 15.6†
-1.00 ± 3.39*
-0.971 ± 1.60*

-0.797 ± 8.23
-0.325 ± 1.99
-0.238 ± 0.988

Values are β ± SE estimates using multivariable survey linear regression. CES-D, 10-Item Center for Epidemiological Studies Depression
Scale; Q, Quartile; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; VLCFA, very long chain omega-3 fatty acids. Omega-3 FA
consumption expressed as percent of total fat intake. †P=0.05 to <0.10; *P<0.05; **P<0.01.
2
Model 1 was adjusted for sex, BMI, age, total energy intake, diabetes status, education level, smoking status, study site, physical activity,
cardiovascular disease status, marital status, Hispanic/Latino background, income, antidepressant use, baseline CES-D score, time between
visits, and intake of total energy, fruit, vegetables, and added sugar. Model 2 adjusting for Model 1 + total omega-6 FA consumption.
3
VLCFA calculated as the sum of EPA, DHA, and DPA (docosapentaenoic acid).
1
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Table 4. Associations between circulating omega-3 FAs and 6-y CES-D score stratified by
quartile of PSS-10 score1,2
PSS-10 Score3

Model 1
EPA
DHA
VLCFA4
Model 2
EPA
DHA
VLCFA4

Q1
6.35 ± 0.2
n=202

Q2
13.06 ± 0.1
n=189

Q3
17.48 ± 0.08
n=170

Q4
23.53 ± 0.29
n=157

0.293 ± 0.775
-0.087 ± 0.403
-0.022 ± 0.246

-0.893 ± 2.17
0.114 ± 0.490
-0.064 ± 0.366

-0.169 ± 0.973
-0.192 ± 0.310
-0.159 ± 0.210

-0.481 ± 1.93
-0.014 ± 0.333
-0.058 ± 0.228

0.296 ± 0.777
-0.088 ± 0.404
-0.022 ± 0.247

-0.906 ± 2.28
0.121 ± 0.483
-0.062 ± 0.364

0.113 ± 0.999
-0.128 ± 0.298
-0.116 ± 0.208

-0.402 ± 2.16
0.079 ± 0.336
0.006 ± 0.240

Values are β ± SE estimates using multivariable survey linear regression. CES-D, 10-Item Center for Epidemiological Studies Depression
Scale; Q, Quartile; PSS-10, 10-Item Perceived Stress Scale; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; VLCFA, very long
chain fatty acids. Circulating omega-3 FA expressed as percent of total circulating fatty acids.*P<0.05.
2
Model 1 was adjusted for sex, BMI, age, total energy intake, diabetes status, education level, smoking status, study site, physical activity,
cardiovascular disease status, marital status, Hispanic/Latino background, income, antidepressant use, baseline CES-D score, time between
visits, and intake of total energy, fruit, vegetables, and added sugar. Model 2 adjusting for Model 1 + total circulating omega-6 FA.
3
Mean ± SE PSS-10 score by quartile.
4
VLCFA calculated as the sum of EPA, DHA, and DPA (docosapentaenoic acid).
1
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Table 5. Associations between circulating omega-3 FAs and 6-y CES-D score stratified by
number of chronic stressors1,2
0
n=316
Model 1
EPA
DHA
VLCFA3
Model 2
EPA
DHA
VLCFA3

Number of Chronic Stressors
1
2
n=168
n=101

3+
n=133

1.14 ± 1.03
0.223 ± 0.327
0.234 ± 0.218

0.314 ± 0.924
0.170 ± 0.292
0.093 ± 0.207

-0.863 ± 3.20**
-0.994 ± 0.618**
-0.937 ± 0.387**

-0.887 ± 1.42†
-0.279 ± 0.327
-0.288 ± 0.230

1.23 ± 1.03
0.228 ± 0.325
0.233 ± 0.218

0.444 ± 0.893
0.204 ± 0.285
0.115 ± 0.200

-0.815 ± 3.30**
-0.993 ± 0.629**
-0.936 ± 0.393**

-0.908 ± 1.48†
-0.277 ± 0.350
-0.292 ± 0.241

Values are β ± SE estimates using multivariable survey linear regression. CES-D, 10-Item Center for Epidemiological Studies Depression
Scale; Q, Quartile; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; VLCFA, very long chain fatty acids. Circulating omega-3 FA
expressed as percent of total circulating fatty acids. †P=0.05 to <0.10, *P<0.05, **P<0.01.
2
Model 1 was adjusted for sex, BMI, age, total energy intake, diabetes status, education level, smoking status, study site, physical activity,
cardiovascular disease status, marital status, Hispanic/Latino background, income, antidepressant use, baseline CES-D score, time between
visits, and intake of total energy, fruit, vegetables, and added sugar. Model 2 adjusting for Model 1 + total circulating omega-6 FA.
3
VLCFA calculated as the sum of EPA, DHA, and DPA (docosapentaenoic acid).
1
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Supplementary Table 1. Sample characteristics by quartile of baseline circulating omega-3
VLCFA1
Circulating Omega-3 VLCFA (Quartile)2
Q1
Q2
Q3
Q4
n=179
n=180
n=180
n=179

P-trend

BMI

32.2 ± 0.78

30.9 ± 0.72

29.5 ± 0.55

30.0 ± 0.94

<0.05

Age, years

38.7 ± 1.4

43.6 ± 1.2

44.0 ± 1.6

49.3 ± 2.3

<0.001

Female, %

51.5

46.9

57.0

48.2

0.07

Dominican, %

3.0

2.0

9.3

18.4

<0.001

Central American, %

6.7

6.2

6.9

3.1

0.07

Cuban, %

13.8

32.1

20.4

20.0

0.47

Mexican,%

43.3

41.0

41.2

26.3

0.28

Puerto Rican, %

23.7

16.0

14.4

23.3

<0.05

South American, %

4.1

2.4

6.3

9.0

0.06

Multiple/Other, %

5.5

0.31

1.6

0

0.07

Bronx, %

23.0

25.0

27.0

46.4

<0.05

Chicago, %

20.6

13.5

9.34

9.67

0.13

Miami, %

27.6

34.8

30.6

23.6

<0.05

San Diego, %

28.8

26.7

33.1

20.4

0.70

<HS, %

28.3

24.7

24.2

22.6

0.53

HS or equivalent, %

33.4

35.1

22.7

20.5

<0.05

>HS, %

38.3

40.3

53.1

57.0

<0.05

Income >$30,000, %

35.5

37.3

36.0

38.6

<0.05

Single, %

43.0

36.7

32.6

16.8

<0.05

Married/Living with a Partner, %

42.2

48.8

50.3

56.1

<0.05

Separated/Divorced, %

14.9

14.5

17.0

27.1

0.41

Diabetes, %

19.4

20.2

10.6

8.49

<0.001

Cardiovascular Disease, %

4.30

3.72

5.05

5.75

0.59

711 ± 147

697 ± 124

615 ± 94.6

658 ± 108

0.77

17.8

27.6

19.9

10.0

<0.05

Hispanic/Latino Background

HCHS Site

Marital Status

Physical Activity, MET-mins/d
Smoking, %
Antidepressant use, %

6.09

5.39

2.32

5.15

0.87

1947 ± 48

2015 ± 46

1913 ± 43

1905 ± 70

<0.05

Vegetables, servings/d

1.86 ± 0.06

1.99 ± 0.07

1.99 ± 0.08

2.07 ± 0.07

0.35

Fruit, servings/d

0.94 ± 0.06

0.96 ± 0.05

1.06 ± 0.06

1.18 ± 0.09

<0.05

Added sugar, g/d

70.9 ± 2.8

68.9 ± 2.1

64.0 ± 2.0

60.1 ± 2.0

<0.001

Dietary VLCFA, % FA

0.18 ± 0.006

0.18 ± 0.008

0.21 ± 0.008

0.24 ± 0.009

<0.001

Dietary EPA, % FA

0.037 ± 0.003 0.037 ± 0.004

0.044 ± 0.004

0.051 ± 0.005

<0.001

Dietary DHA, % FA

0.11 ± 0.003

0.12 ± 0.005

0.14 ± 0.005

<0.001

Energy, Kcals/d

0.11 ± 0.005
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Dietary Total Omega-6 FA, % FA

19.56 ± 0.3

19.51 ± 0.3

19.93 ± 0.2

19.67 ± 0.3

1.00

Baseline CES-D score

5.7 ± 0.1

5.5 ± 0.2

5.6 ± 0.1

4.3 ± 0.1

0.05

6-y CES-D score

5.6 ± 0.2

5.5 ± 0.2

3.9 ± 0.2

3.4 ± 0.2

<0.05

PSS-10 score

15.4 ± 0.6

15.0 ± 0.7

13.9 ± 0.5

12.1 ± 0.5

<0.001

Number of Chronic Stressors

1.7 ± 0.2

1.3 ± 0.2

1.1 ± 0.1

1.1 ± 0.2

<0.05

Circulating EPA, % FA

0.07 ± 0.003

0.10 ± 0.01

0.13 ± 0.004

0.23 ± 0.01

<0.001

Circulating DHA, % FA

0.40 ± 0.01

0.57 ± 0.01

0.74 ± 0.01

1.10 ± 0.03

<0.001

Circulating VLCFA, % FA

0.61 ± 0.01

0.85 ± 0.01

1.09 ± 0.01

1.59 ± 0.05

<0.001

Circulating Omega-6 FA, % FA

19.8 ± 0.3

19.5 ± 0.2

19.9 ± 0.2

20.1 ± 0.3

0.31

1

Values are age- and sex-adjusted means ± SE or proportions by quartile of circulating omega-3 VLCFA as % total circulating fatty acids using
proc surveyreg and proc freq, respectively, in SAS. Q, quartile; HCHS, Hispanic Community Health Study; HS, high school education; MET,
metabolic equivalent; CES-D, 10-item Center for Epidemiological Studies Depression Scale; PSS-10, 10-Item Perceived Stress Scale; EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid; VLCFA, very long chain fatty acids.
2
VLCFA calculated as the sum of EPA, DHA, and DPA (docosapentaenoic acid).
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Supplementary Table 2. Associations between baseline omega-3 FA consumption and 6-y CES-D score excluding fish oil users1,2
Unstratified
Model 1
EPA
DHA
VLCFA3
Model 2
EPA
DHA
VLCFA3

PSS-10 Score
Q3

Q4

0

Number of Chronic Stressors
1
2

Q1

Q2

3+

-0.946 ± 2.28
-0.877 ± 0.879*
-0.614 ± 0.447*

26.1 ± 6.06*
2.01 ± 1.99
1.11 ± 0.939

-0.998 ± 5.70*
-0.816 ± 1.49
-0.640 ± 0.773

-0.992 ± 6.68
-0.979 ± 1.89*
-0.720 ± 0.915

-1.00 ± 5.31†
-0.980 ± 1.58*
-0.833 ± 0.799*

-0.621 ± 3.94
-0.715 ± 1.46
-0.438 ± 0.699

-0.926 ± 9.42
-0.889 ± 2.34
-0.506 ± 1.15

-0.753 ± 17.0
-1.00 ± 3.52*
-0.951 ± 1.64†

-0.889 ± 7.39
-0.558 ± 1.90
-0.375 ± 0.935

-0.919 ± 2.41
-0.863 ± 0.936*
-0.592 ± 0.474*

26.8 ± 6.09*
2.09 ± 2.00
1.15 ± 0.944

-0.999 ± 5.81†
-0.792 ± 1.51
-0.620 ± 0.788

-0.999 ± 7.70
-0.993 ± 2.04*
-0.786 ± 0.994†

-1.00 ± 5.32
-0.932 ± 1.56†
-0.731 ± 0.800†

-0.733 ± 4.20
-0.784 ± 1.58
-0.510 ± 0.746

-0.186 ± 9.11
-0.513 ± 2.24
-0.015 ± 1.11

-0.433 ± 18.3†
-1.00 ± 3.94*
-0.974 ± 1.81*

-0.611 ± 8.29
-0.249 ± 2.02
-0.160 ± 0.999

Values are β ± SE estimates using multivariable survey linear regression. CES-D 10, 10-Item Center for Epidemiological Studies Depression Scale; Q, Quartile; PSS-10, 10-Item Perceived Stress
Scale; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; VLCFA, very long chain fatty acids. Omega-3 FA consumption expressed as % of total fat intake. N=272 (8%) of original analytic
sample used fish oil supplement. †P=0.05 to <0.10; *P<0.05; **P<0.01.
2
Model 1 was adjusted for sex, BMI, age, total energy intake, diabetes status, education level, smoking status, study site, physical activity, cardiovascular disease status, marital status, Hispanic/Latino
background , income, antidepressant use, baseline CES-D score, time between visits, and intake of total energy, fruit, vegetables, and added sugar. Model 2 adjusting for Model 1 + total omega-6 FA
consumption.
3
VLCFA calculated as the sum of EPA, DHA, and DPA (docosapentaenoic acid).
1
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Supplementary Table 3. Associations between baseline circulating omega-3 FA and 6-y CES-D score excluding fish oil users1,2
Unstratified
Model 1
EPA
DHA
VLCFA3
Model 2
EPA
DHA
VLCFA3

Q1

PSS-10 Score
Q2
Q3

Q4

0

Number of Chronic Stressors
1
2

3+

-0.358 ± 1.107
-0.144 ± 0.282
-0.129 ± 0.211

1.19 ± 1.05
0.195 ± 0.495
0.174 ± 0.291

-0.895 ± 2.523
0.079 ± 0.595
-0.119 ± 0.434

-0.083 ± 1.31
0.158 ± 0.342
0.044 ± 0.248

-0.879 ± 2.75
-0.348 ± 0.379
-0.314 ± 0.272

1.35 ± 1.19
0.238 ± 0.350
0.250 ± 0.230

0.590 ± 4.24
0.421 ± 0.354
0.255 ± 0.305

-0.031 ± 4.62**
-1.00 ± 0.654**
-0.980 ± 0.427**

-0.837 ± 1.34
-0.212 ± 0.309
-0.246 ± 0.218

-0.287 ± 1.097
-0.138 ± 0.281
-0.125 ± 0.210

1.16 ± 1.09
0.200 ± 0.501
0.183 ± 0.298

-0.890 ± 2.57
0.063 ± 0.579
-0.127 ± 0.427

0.978 ± 1.30
0.359 ± 0.330
0.208 ± 0.241

-0.875 ± 2.81
-0.339 ± 0.374
-0.309 ± 0.272

1.42 ± 1.17
0.253 ± 0.348
0.250 ± 0.229

1.04 ± 4.02
0.474 ± 0.344
0.292 ± 0.295

0.521 ± 4.875**
-1.00 ± 0.668**
-0.980 ± 0.429**

-0.820 ± 1.41
-0.176 ± 0.327
-0.225 ± 0.230

Values are β ± SE estimates using multivariable survey linear regression. CES-D 10, 10-Item Center for Epidemiological Studies Depression Scale; Q, Quartile; PSS-10, 10-Item Perceived Stress
Scale; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; VLCFA, very long chain fatty acids. Omega-3 FA expressed as % of total circulating fatty acids. N=48 (7%) of original analytic cohort
used a fish oil supplement. †P=0.05 to <0.10; *P<0.05; **P<0.01.
2
Model 1 was adjusted for sex, BMI, age, total energy intake, diabetes status, education level, smoking status, study site, physical activity, cardiovascular disease status, marital status, Hispanic/Latino
background , income, antidepressant use, baseline CES-D score, time between visits, and intake of total energy, fruit, vegetables, and added sugar. Model 2 adjusting for Model 1 + total circulating
omega-6 FA.
3
VLCFA calculated as the sum of EPA, DHA, and docosapentaenoic acid (DPA).
1
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Figure 1. Eligibility criteria for analytic sample

HCHS/SOL Wave 1
n=16,415

WGS and Metabolomics
Ancillary Study
n=3,978

Sociocultural Ancillary Study
n=5,313

HCHS/SOL Wave 2
n=11,623

Dietary Analyses
n=3,537
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Metabolomic Analyses
n=718

46
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Figure 4. Biological plausibility of omega-3 FA on depressive symptoms and effect of psychological stress
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